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Background: Amiodarone is a useful antiarrhythmic drug, especially in patients with serious heart
diseases, but amiodarone-induced interstitial pneumonia (AMD-IP) is sometimes lethal.
Methods and results: We retrospectively analyzed the clinical characteristics of 280 patients who were
treated with daily oral amiodarone. Among the patients, 29 (10.2%) developed AMD-IP during the
follow-up period of 66.0738.2 months. The average dose of amiodarone in the AMD-IP group
(173710 mg) was signiﬁcantly higher than that in the non-AMD-IP group (15073 mg). The
prevalence of smoking history (AMD-IP group: 70.0%; non-AMD-IP group: 42.2%; Po0.01) and
underlying lung disease (AMD-IP group: 17.2%; non-AMD-IP group: 5.6%; Po0.05) was signiﬁcantly
higher in the AMD-IP group than in the non-AMD-IP group. Furthermore, multiple stepwise logistic
regression analysis demonstrated that smoking history was an independent predictor of AMD-IP (OR,
3.56; 95% CI, 1.08–10.23; Po0.001). Among patients who developed AMD-IP, those with chronic
obstructive pulmonary disease (COPD) had a higher relapse rate and a worse prognosis.
Conclusions: During the mean follow-up period of 45 years, 10.2% of patients receiving low-dose
amiodarone therapy developed AMD-IP. Higher maintenance doses, smoking history, and preexisting
lung disease were related to the development of AMD-IP. The AMD-IP patients with COPD had a poor
prognosis.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Sudden cardiac death (SCD) in patients with low ventricular
function remains a substantial problem despite improved medical
therapies [1–3]. Many patients require antiarrhythmic drugs to
prevent recurrent arrhythmias and reduce the number of shocks
from implanted cardioverter-deﬁbrillators (ICDs) [4]. Amiodar-
one, a class III antiarrhythmic drug, which prolongs myocardial
repolarization homogeneously via potassium channel blockade,
has been used extensively to treat life-threatening arrhythmias.
The major forms of amiodarone toxicity during chronic therapy
are extracardiac [5]. Several adverse effects in many organs have
been reported [5]. Among these, amiodarone toxicity, interstitial
pneumonia, and pulmonary ﬁbrosis are the most life-threatening
[5,6]. According to previous studies, amiodarone-induced pulmon-
ary toxicity has been observed in 1%–20% of patients receiving thisrt Rhythm Society. Published by E
: þ81 96 326 3045.drug [5,7–9], and there may be ethnic or racial differences in the
susceptibility [7,10].
Early detection is needed to prevent amiodarone-induced inter-
stitial pneumonia (AMD-IP). However, it has been difﬁcult to predict
which patients are at the greatest risk of the development of AMD-IP
[11]. The aims of this study were to evaluate the incidence and
prognosis of AMD-IP and to identify the predictors of AMD-IP in
Japanese patients treated with low-dose oral amiodarone.2. Methods
2.1. Study subjects
From January 2004 to May 2009, 373 patients were treated with
oral amiodarone in Saiseikai Kumamoto Hospital Cardiovascular
Center. Many previous studies have shown that AMD-IP shortly after
starting amiodarone was rare [5,7–9]; therefore, we focused on the
patients undergoing maintenance therapy with daily amiodarone.lsevier B.V. All rights reserved.
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Fig. 1. (A) Kaplan–Meier analysis showing the incidence of amiodarone-induced
interstitial pneumonia (AMD-IP). Among 280 patients who received daily amio-
darone longer than 2 months, 29 developed AMD-IP during the observation
period. (B) Survival ratio in AMD-IP and non-AMD-IP. Kaplan–Meier analysis
revealed that the patients who developed AMD-IP had a poor prognosis (Po0.05).
Only 5 patients died from acute respiratory failure directly due to AMD-IP.
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ued amiodarone therapy for more than 2 months.
2.1. Diagnosis of AMD-IP and extrapulmonary side effects
Several previous studies have shown that underlying lung
disease was associated with the development of AMD-IP [12]. In
patients who had underlying lung diseases such as emphysema, we
avoided amiodarone therapy if possible. However, some patients
with underlying lung disease needed amiodarone therapy because
of lethal ventricular arrhythmias or frequent ICD shocks. At the
beginning of amiodarone therapy, we evaluated the computed
tomographic (CT) images and the pulmonary function tests in all
cases, and we avoided amiodarone therapy in patients who had a
background of obvious pulmonary ﬁbrosis. Underlying lung disease
in this study was deﬁned as chronic obstructive pulmonary disease
(COPD), bronchial asthma, and old tuberculosis.
The maintenance doses were adjusted according to the indivi-
dual patient’s conditions at a range of 50–200 mg. All patients
received follow-up every 3 months at our outpatient clinic. Routine
tests included physical examination, chest radiography, and serum
KL-6 measurement. The diagnosis of AMD-IP was performed by
more than 2 physicians on the basis of clinical data, namely, new
onset of pulmonary symptoms such as dyspnea, cough, and pleuritic
chest pain with pulmonary ﬁbrosis on the CT image. Chest radio-
graphic abnormalities, including pulmonary edema caused by con-
gestive heart failure, infective pneumonia, and malignancy, were
excluded. The patients who discontinued amiodarone only because
of a marked increase of serum KL-6 without other evidence were not
considered as having AMD-IP.
We also evaluated thyroid functions and serum transaminase
routinely every 6 months. Thyroid abnormalities and liver dys-
function, which required dose reduction or additional medical
therapy, were deﬁned as extrapulmonary side effects.
2.3. Statistical analysis
Continuous variables, presented as mean7standard deviation,
were compared by unpaired Student’s t-test. Categorical vari-
ables, presented as frequency and percentage, were compared
using chi-square test or Fisher’s test as appropriate. The cumula-
tive incidence was estimated using Kaplan–Meier analysis from
the initiation of drug administration to the last observation day or
the day of AMD-IP onset. Po0.05 was considered to indicate
statistical signiﬁcance. All statistical analyses were performed
using StatView version 5.0 (SAS Institute, Cary, NC, USA).3. Results
3.1. Incidence of AMD-IP
Among 280 patients who received daily amiodarone for more
than 2 months, 29 (10.2%) developed AMD-IP during the observa-
tion period. The Kaplan–Meier curve, which demonstrates the
incidence of AMD-IP, is shown in Fig. 1A. Mean follow-up period
was 66.0738.2 months, and mean duration from initiation of
amiodarone therapy to onset of AMD-IP was 31.9725.2 months.
In all patients diagnosed as having AMD-IP, amiodarone was
discontinued, and they received corticosteroid therapy.
3.2. Patient characteristics and dosage of amiodarone
The characteristics of patients who received amiodarone therapy
are shown in Table 1A. Mean age at the start of amiodarone therapy
was 67.3712.5 years. There were no signiﬁcant differencesbetween the AMD-IP and non-AMD-IP groups in age, gender, body
mass index (BMI), and left ventricular ejection fraction (EF). A large
percentage of patients had organic heart diseases, such as dilated
cardiomyopathy, hypertrophic cardiomyopathy, and ischemic cardi-
omyopathy (mean EF, 38.9%), but the causes of organic heart
diseases were not signiﬁcantly different between the AMD-IP and
non-AMD-IP groups (Table 1A).
Underlying lung disease was correlated with a higher inci-
dence of AMD-IP (AMD-IP group: 17.2%; non-AMD-IP group:
5.6%; Po0.05). Furthermore, the prevalence of smoking history
was signiﬁcantly higher in the AMD-IP group than in the non-
AMD-IP group (AMD-IP group: 70.0%; non-AMD-IP group: 42.2%;
Po0.01; Table 1A). Multiple stepwise logistic regression analysis
of clinical variables demonstrated that only smoking history was
a signiﬁcant independent predictor of AMD-IP (Table 1C).
Medical treatments were not signiﬁcantly different between
the AMD-IP and non-AMD-IP groups (Table 1B). However, the
maintenance doses of amiodarone were signiﬁcantly higher in the
AMD-IP group than in the non-AMD-IP group (AMD-IP group:
173710 mg; non-AMD-IP group: 15073 mg; Po0.05; Fig. 2A).3.3. Extrapulmonary side effects and AMD-IP
Thyroid abnormality, which required additional medical ther-
apy, was observed in 35 of 280 patients (12.5%). Liver dysfunction,
which required a dose reduction of amiodarone, was seen in 3 of
280 patients (1.1%). Neither the incidence of thyroid abnormal-
ities nor that of liver dysfunction was different between the AMD-
IP and non-AMD-IP groups (thyroid dysfunction: AMD-IP, 5
[18.5%]; non-AMD-IP, 30 [11.8%]; liver dysfunction: AMD-IP, 0
[0%]; non-AMD-IP, 3 [1.2%]). Extrapulmonary side effects were
not common in AMD-IP patients.
Table 1
(A) Patient characteristics. The prevalence of smoking history (AMD-IP group:
70.0%; non-AMD-IP group: 42.2%; Po0.01) and underlying lung disease (AMD-IP
group: 17.2%; non-AMD-IP groups: 5.6%; Po0.05) were signiﬁcantly higher in the
AMD-IP group than in the non-AMD-IP group. Data are presented as mean
value7SD or number (%) of patients. EF¼ left ventricular ejection fraction,
BMI¼body mass index, DCM¼dilated cardiomyopathy, HCM¼hypertrophic car-
diomyopathy, ICM¼ ischemic cardiomyopathy, VT¼ventricular tachycardia. (B)
Medications were not different between the AMD-IP and non-AMD-IP groups.
ARB¼angiotensin II receptor blocker. (C) Multiple stepwise logistic regression
analysis of clinical variables demonstrated that only smoking history was a
signiﬁcant independent predictor of AMD-IP (Table 1C). OR¼odds ratio, CI¼conﬁ-
dence interval.
(A)
AMD-IP non-AMD-IP P
n 29 251
Agge (y.o.) 69.6713.6 67.0712.3 NS
Gender (Male) 25 (86.2%) 187 (74.5%) NS
EF (%) 36.8712.7 39.2715.3 NS
BMI 22.573.6 22.973.7 NS
DCM 8 (27.5%) 74 (29.5%) NS
HCM 6 (20.7%) 56 (22.3%) NS
ICM 13 (44.8%) 73 (29.1%) NS
Valvular disease 2 (6.9%) 19 (7.6%) NS
Congenital disease 0 (0%) 6 (2.4%) 
Idiopathic VT 0 (0%) 6 (2.4%) 
Others 0 (0%) 17 (6.8%) 
Lung disease 5 (17.2%) 14 (5.6%) o0.05
Smoking history 20 (70.0%) 106 (42.2%) o0.05
(B)
AMD-IP non-AMD-IP P
n 25 246
ACE inhibitors 8 (32%) 95 (38.6%) NS
ARB 5 (20.0%) 81 (32.9%) NS
b blockers 21 (84.0%) 183 (74.4%) NS
Statins 5 (20.0%) 64 (26.0%) NS
Diuretics 19 (76.0%) 144 (58.5%) NS
Digitalis 5 (20.0%) 25 (10.2%) NS
(C)
Valiables OR 95% CI P value
Lung disease 3.08 1.39–7.37 0.07
Smoking history 3.56 1.08–10.23 o0.01
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Fig. 2. Maintenance doses of amiodarone. (A) Maintenance doses of amiodarone
were signiﬁcantly higher in the AMD-IP group than in the non-AMD-IP group
(AMD-IP group: 173710 mg, n¼29; non-AMD-IP group: 15073 mg, n¼251;
Po0.05). (B) Among patients who developed AMD-IP, patients with COPD had
higher mortality than those without COPD.
Table 2
(A) Causes of death in AMD-IP patients. The number of sudden cardiac deaths was
signiﬁcantly higher in the AMD-IP group than in the non-AMD-IP group. Five
AMD-IP patients died directly because of respiratory failure caused by AMD-IP.
(B) AMD-IP patients with COPD had a higher relapse rate and poor prognosis.
(A)
AMD-IP non-AMD-IP P
n 29 251
Total death 17 38
CHF 5 (29.4%) 21 (55.3%) NS
Sudden death 4 (23.5%) 4 (10.5%) o0.01
AMD-IP 5 (29.4%) 0 (0%) 
Others 3 (17.6%) 13 (34.2%) NS
(B)
with COPD without COPD P
n 5 24
Relapse of AMD-IP 5 (100%) 1 (4.1%) o0.01
Death for AMD-IP 3 (60%) 2 (8.3%) o0.05
Total death 5 (100%) 12 (50%) o0.01
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Among 280 patients treated with oral amiodarone as main-
tenance therapy, 55 (19.6%) died of any cause during our follow-
up period. As shown in Fig. 1B, the Kaplan–Meier analysis
revealed that the patients who developed AMD-IP had a poor
prognosis. Five patients died of acute respiratory failure directly
due to AMD-IP (1.8%), even though all patients who developed
AMD-IP received oral or intravenous corticosteroid therapy.
Furthermore, we found that the incidence of SCD was signiﬁcantly
higher in the AMD-IP group than in the non-AMD-IP group (AMD-
IP group: 23.5%; non-AMD-IP: 10.5%; Table 2A).
3.5. AMD-IP and underlying lung disease
In this study, the patients who developed AMD-IP were more
likely to have underlying lung disease (AMD-IP group: 17.2%;
non-AMD-IP group: 5.6%; Po0.05; Table 1A). Furthermore, AMD-
IP patients with COPD had a higher relapse rate and poor survival
(Fig. 2B). We observed 6 relapse cases of AMD-IP after initial
treatment including corticosteroid therapy. In these relapse cases,
5 patients had COPD (Table 2B). The deaths of 3 of these patients
were directly attributed to respiratory failure caused by AMD-IP(Table 2B.) All AMD-IP patients with COPD died during our
observation period.4. Discussion
Amiodarone is an antiarrhythmic drug, which is widely used
around the world. However, its pulmonary side effects are some-
times lethal. In this study, we found that 10.2% of patients
developed AMD-IP during prolonged low-dose amiodarone
M. Nozoe et al. / Journal of Arrhythmia 29 (2013) 5–88therapy (mean follow-up period, 66.0738.2 months). We show
2 major ﬁndings. First, although the maintenance doses of this
observation was relatively low compared to that of previous
studies (mean dosage, 152 mg/day) [1–5], higher maintenance
doses were related to the occurrence of AMD-IP. Second, the
patients with a smoking history and preexisting COPD were more
likely to develop AMD-IP. In particular, we showed for the ﬁrst
time that smoking history was an independent predictor of AMD-
IP. In addition, the AMD-IP patients with COPD had a poor
prognosis resulting from relapsing AMD-IP.
Neurologic and gastrointestinal tract toxicity of amiodarone
are dose related [6,13], but pulmonary toxicity has been reported
to be related in part to drug dosage [6,13–15]. It has been
reported that pulmonary toxicity is uncommon at maintenance
doses less than 300 mg/day [14,15]. Some studies indicate that
there is no statistically signiﬁcant difference in the rate of
pulmonary adverse effects between placebo and low-dose amio-
darone [13,16]. However, AMD-IP can occur during prolonged
therapy with doses at below 200 mg/day [17,18]. The average
dose of amiodarone in the present study was relatively low
(152 mg/day) compared with previous studies; however, the
doses used in the AMD-IP group were signiﬁcantly higher than
those in the non-AMD-IP group. Yamada et al. reported the
incidence of AMD-IP to be 7.8% and 10.6% at 3 and 5 years,
respectively, even though the mean maintenance dose was only
141 mg/day in their study [10].
AMD-IP was signiﬁcantly associated with a poor prognosis.
Mortality in AMD-IP is reported to range between 21% and 33% in
patients who were admitted to the hospital [9,19–21]. In the
present study, AMD-IP was not only a major cause of acute
respiratory failure leading to death but also increased the risk of
SCD. We use amiodarone commonly for ventricular arrhythmia
patients with organic heart disease and poor left ventricular
function, rather than atrial arrhythmias. For patients with poor
left ventricular function, AMD-IP might worsen heart failure
caused by hypoxemia and secondary pulmonary hypertension,
and withdrawal of amiodarone may result in sudden death or
poor prognosis.
Higher age [7,9], cumulative dosage [5], reduced predrug
diffusion capacity [12], underlying lung disease [5,7–9,22,23],
and recent pulmonary insults [5] are reported to be risk factors
of AMD-IP. Although it is arguable whether pulmonary toxicity
occurs to a greater degree in patients who have underlying
pulmonary disease, such as COPD [6,11], we clearly showed that
the likelihood of developing AMD-IP was higher in patients with
COPD and a smoking history than in patients without COPD or a
smoking history. Many studies support our results that COPD is a
risk factor for AMD-IP [23–25]. However, we showed for the ﬁrst
time that smoking history per se could predict AMD-IP. The
mechanisms of pulmonary toxicity are unclear, but amiodarone
may interfere with lysosomal phospholipases, leading to phos-
pholipidosis [26]. It has been suggested that an immunologic
reaction may also produce a hypersensitivity response [22]. Some
studies have suggested that preexisting lung disease might pre-
dispose the patient to lung toxicity [12,27], even though this has
not been veriﬁed by other studies [25,28]. We also showed that
patients with COPD had a higher relapse rate and poor prognosis.
This is the ﬁrst report demonstrating that smoking history
itself might predict the development of AMD-IP. Patients on
amiodarone who have COPD and a smoking history should be
monitored carefully and routinely for pulmonary side effects.
Conﬂict of interest
None.References
[1] Wyse DG, Friedman PL, Brodsky MA, et al. AVID Investigators. Life-
threatening ventricular arrhythmias due to transient or correctable causes:
high risk for death in follow-up. J Am Coll Cardiol 2001;38:1718–24.
[2] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-
deﬁbrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
[3] Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amio-
darone on mortality after acute myocardial infarction and in congestive heart
failure: meta-analysis of individual data from 6500 patients in randomised
trials. Amiodarone Trials Meta-Analysis Investigators. The Lancet. 1997; 350:
1417–1424.
[4] Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers,
amiodarone plus beta-blockers, or sotalol for prevention of shocks from
implantable cardioverter deﬁbrillators: the OPTIC study: a randomized trial.
JAMA 2006;295:165–71.
[5] Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review
of clinical indications. JAMA 2007;298:1312–22.
[6] Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for
clinicians who treat patients with amiodarone. Practice Guidelines Subcom-
mittee, North American Society of Pacing and Electrophysiology. Arch Intern
Med 2000;160 1741-8.
[7] Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009;16:
43–8.
[8] Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. BMJ 1997;314:
619–20.
[9] Camus P, Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Clin Chest
Med 2004;25:65–75.
[10] Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary
toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007;71
1610-6.
[11] Hawthorne HR, Wood MA, Stambler BS, et al. Can amiodarone pulmonary
toxicity be predicted in patients undergoing implantable cardioverter deﬁ-
brillator implantation? Pacing Clin Electrophysiol 1993;16:2241–9.
[12] Ohar JA, Jackson Jr F, Redd RM, et al. Usefulness of serial pulmonary function
testing as an indicator of amiodarone toxicity. Am J Cardiol 1989;64:1322–6.
[13] Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose
amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791–8.
[14] Kowey PR, Friehling TD, Marinchak RA, et al. Safety and efﬁcacy of
amiodarone. The low-dose perspective. Chest 1988;93:54–9.
[15] Kerin NZ, Aragon E, Faitel K, et al. Long-term efﬁcacy and toxicity of high-
and low-dose amiodarone regimens. J Clin Pharmacol 1989;29:418–23.
[16] Dimopoulou I, Marathias K, Daganou M, et al. Low-dose amiodarone-related
complications after cardiac operations. J Thorac Cardiovasc Surg 1997;114:
31–7.
[17] Ott MC, Khoor A, Leventhal JP, et al. Pulmonary toxicity in patients receiving
low-dose amiodarone. Chest 2003;123:646–51.
[18] Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after
myocardial infarction in patients with frequent or repetitive ventricular
premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial
Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675–82.
[19] Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodarone-induced pulmon-
ary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol
2010;99:693–700.
[20] Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneumonitis. Bronch-
oalveolar lavage ﬁndings in 15 patients and review of the literature. Chest
1992;102:1005–12.
[21] Oyama N, Oyama N, Yokoshiki H, et al. Detection of amiodarone-induced
pulmonary toxicity in supine and prone positions: high-resolution computed
tomography study. Circ J 2005;69:466–70.
[22] Akoun GM, Gauthier-Rahman S, Milleron BJ, et al. Amiodarone-induced
hypersensitivity pneumonitis. Evidence of an immunological cell-mediated
mechanism. Chest 1984;85:133–5.
[23] Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991;121:
158–71.
[24] Singh SN, Fisher SG, Deedwania PC, et al. Pulmonary effect of amiodarone in
patients with heart failure. the congestive heart failure-survival trial of
antiarrhythmic therapy (CHF-STAT) investigators (Veterans Affairs Coopera-
tive Study no. 320). J Am Coll Cardiol 1997;30:514–7.
[25] Kudenchuk PJ, Pierson DJ, Greene HL, et al. Prospective evaluation of
amiodarone pulmonary toxicity. Chest 1984;86:541–8.
[26] Dean PJ, Groshart KD, Porterﬁeld JG, et al. Amiodarone-associated pulmon-
ary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol
1987;87:7–13.
[27] Kennedy JI, Myers JL, Plumb VJ, et al. Amiodarone pulmonary toxicity. Clinical,
radiologic, and pathologic correlations. Arch Intern Med 1987;147:50–5.
[28] Magro SA, Lawrence EC, Wheeler SH, et al. Amiodarone pulmonary toxicity:
prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol
1988;12:781–8.
